Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma

The prognosis of advanced hepatocellular carcinoma (HCC) patients remains extremely poor, partially due to the development of acquired resistance to sorafenib and chemotherapy. Cabazitaxel, a semisynthetic taxane, has been approved for the therapy of docetaxel-resistant prostate cancer. However, no...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cancer Res
Hlavní autoři: Chen, Ronggao, Cheng, Qiyang, Owusu-Ansah, Kwabena Gyabaah, Chen, Jun, Song, Guangyuan, Xie, Haiyang, Zhou, Lin, Xu, Xiao, Jiang, Donghai, Zheng, Shusen
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6079161/
https://ncbi.nlm.nih.gov/pubmed/30094102
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky